A Phase I Investigation of the Safety, Tolerability and Immunogenicity of V934/V935 hTERT Vaccination in Cancer Patients With Selected Solid Tumours.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 10 May 2022

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs V 935 (Primary)
Indications Advanced breast cancer; Bladder cancer; Colon cancer; Gallbladder cancer; Gastric cancer; Gastrointestinal cancer; Malignant melanoma; Non-small cell lung cancer; Oesophageal cancer; Pancreatic cancer; Prostate cancer; Renal cell carcinoma; Solid tumours
Focus Adverse reactions
Sponsors Merck Sharp & Dohme

24 Apr 2012 Actual patient number is 37 according to ClinicalTrials.gov.
19 May 2011 Actual end date (Apr 2011) added as reported by ClinicalTrials.gov.
19 May 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com